Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PDCD1) · developed by Novartis Pharmaceuticals
Spartalizumab is a humanized IgG4 monoclonal antibody that binds PD-1 on activated T cells and blocks its ligands PD-L1 and PD-L2, relieving PD-1-mediated inhibition of T-cell activation. It is being studied in non-small-cell lung carcinoma, melanoma, nasopharyngeal carcinoma, microsatellite stable colorectal cancer and triple negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
Carcinoma, Non-Small-Cell LungMelanomaMicrosatellite Stable Colorectal CancerNasopharyngeal CarcinomaTriple Negative Breast Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →